APIs and Excipients

Learning to Think at Lightspeed

April 15, 2023

Actions combatting the next pandemic must be diverse, reliable, and sustainable.

Managing mRNA Instability

April 15, 2023

Unique solutions are required to protect inherently unstable messenger RNA.

The Role of Separation Techniques in the Analysis of mRNA Therapeutic Drug Substances and Drug Products

April 15, 2023

This article reviews a range of techniques available for separative analysis of mRNA therapeutics, their associated impurities, and delivery vehicles.

The Marriage of RNA and Mass Spectrometry

April 15, 2023

Considerable efforts have been made over the years to resolve the key issues of stability and delivery of RNA-based therapeutics.

Delivering on the Potential of mRNA Therapeutics

April 15, 2023

The complexity of the RNA production process creates challenges.

Caribou Biosciences Gets FDA Granted Fast Track Designation for Allogeneic CAR-T Cell Therapy

April 14, 2023

FDA has granted fast track designation to Caribou Biosciences for its allogeneic CAR-T cell therapy for relapsed or refractory multiple myeloma.

Formulating Drugs for Continuous Processing

April 03, 2023

Despite the advantages intensified processes can offer developers, there are still some obstacles to overcome before broader application of new technologies will be implemented.

Quality Challenges Associated with Cryo/Lyoprotectants

April 03, 2023

Impurities and batch-to-batch variability present the biggest challenges.

PharmaBlock Opens New R&D Facility in Pennsylvania

March 27, 2023

PharmaBlock has opened a new R&D facility in Pennsylvania, expanding its capacity to deliver GMP projects.

Curia and Corning Collaborate to Advance Biopharmaceutical Continuous-Flow Development

March 24, 2023

Curia is collaborating with Corning to advance biopharmaceutical continuous-flow development and manufacturing programs.